摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2R,3R,αR)-tert-butyl 2-hydroxy-3-(N-benzyl-N-α-methylbenzylamino)butanoate | 161453-10-7

中文名称
——
中文别名
——
英文名称
(2R,3R,αR)-tert-butyl 2-hydroxy-3-(N-benzyl-N-α-methylbenzylamino)butanoate
英文别名
tert-butyl (2R,3R,αR)-3--2-hydroxybutyrate;tert-butyl (2R,3R,αR)-3-(N-benzyl-N-α-methylbenzylamino)-2-hydroxybutanoate;tert-butyl (R,R,R)-2-hydroxy-3-[N-benzyl-N-(a-methylbenzyl)amino]butanoate;tert-butyl (R,R,R)-2-hydroxy-3-[N-benzyl-N-(α-methylbenzyl)amino]butanoate;tert-butyl (2R,3R)-3-[benzyl-[(1R)-1-phenylethyl]amino]-2-hydroxybutanoate
(2R,3R,αR)-tert-butyl 2-hydroxy-3-(N-benzyl-N-α-methylbenzylamino)butanoate化学式
CAS
161453-10-7
化学式
C23H31NO3
mdl
——
分子量
369.504
InChiKey
JRBPZDZFCLSTDV-DBXWQHBBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    474.0±40.0 °C(Predicted)
  • 密度:
    1.082±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    27
  • 可旋转键数:
    9
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    49.8
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (2R,3R,αR)-tert-butyl 2-hydroxy-3-(N-benzyl-N-α-methylbenzylamino)butanoate甲醇4-二甲氨基吡啶 、 sodium tetrahydroborate 、 草酰氯 、 10 wt% Pd(OH)2 on carbon 、 氢气二甲基亚砜三乙胺 作用下, 以 二氯甲烷乙酸乙酯 为溶剂, -78.0~20.0 ℃ 、506.66 kPa 条件下, 反应 31.0h, 生成 tert-butyl (2S,3R)-2-methanesulfonyloxy-3-[(tert-butoxycarbonyl)amino]butanoate
    参考文献:
    名称:
    交易Ñ和ö:β羟基α氨基的不对称合成氨基酸经由α羟基-β氨基酯
    摘要:
    2-氨基-3-羟基丁酸和2-氨基-3-羟基-3-苯基丙酸的非对映体都已经从对映纯的α羟基-β氨基酯通过相应的中间性制备顺式和-反式-aziridines。2个α的氨羟化,β -不饱和酯制备对映纯的2,3-反-α羟基-β-氨基> 99酯:1个博士。在通过连续的氧化/还原非对映选择性的协议C(2) -位随后差向异构化,得到相应的对映体纯2,3-顺-α-羟基-β氨基酯在> 99:1个博士。这些顺式-和反然后-substrates被转化成相应的Ñ -Boc保护的顺式-和反式-aziridines,分别经由三步反应过程:(i)氢解和就地Ñ -Boc保护; (ii)OH活化;和(iii)氮丙啶的形成。随后的区域选择性的C(3) -甲基氮丙啶的有Cl开环3 CCO 2 ħ继续进行配置,以得到相应的2-氨基-3-三氯乙酸酯的反转,而与C(3)的类似反应-苯基-氮丙啶导致重排为相应的恶唑烷-2-酮与结构的保
    DOI:
    10.1016/j.tet.2013.08.007
  • 作为产物:
    参考文献:
    名称:
    Nine Enzymes Are Required for Assembly of the Pacidamycin Group of Peptidyl Nucleoside Antibiotics
    摘要:
    Pacidamycins are a family of uridyl peptide antibiotics that inhibit the translocase MraY, an essential enzyme in bacterial cell wall biosynthesis that to date has not been clinically targeted. The pacidamycin structural skeleton contains a doubly inverted peptidyl chain with a beta-peptide and a ureido linkage as well as a 3'-deoxyuridine nucleoside attached to DABA(3) of the peptidyl chain via an enamide linkage. Although the biosynthetic gene cluster for pacidamycins was identified recently, the assembly line of this group of peptidyl nucleoside antibiotics remained poorly understood because of the highly dissociated nature of the encoded nonribosomal peptide synthetase (NRPS) domains and modules. This work has identified a minimum set of enzymes needed for generation of the pacidamycin scaffold from amino acid and nucleoside monomers, highlighting a freestanding thiolation (T) domain (PacH) as a key carrier component in the peptidyl chain assembly as well as a freestanding condensation (C) domain (PacI) catalyzing the release of the assembled peptide by a nucleoside moiety. On the basis of the substrate promiscuity of this enzymatic assembly line, several pacidamycin analogues were produced using in vitro total biosynthesis.
    DOI:
    10.1021/ja2011109
点击查看最新优质反应信息

文献信息

  • From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: The discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis
    作者:Joseph B. Santella、Daniel S. Gardner、Wenqing Yao、Chongsheng Shi、Prabhakar Reddy、Andrew J. Tebben、George V. DeLucca、Dean A. Wacker、Paul S. Watson、Patricia K. Welch、Eric A. Wadman、Paul Davies、Kimberly A. Solomon、Dani M. Graden、Swamy Yeleswaram、Sandhya Mandlekar、Ilona Kariv、Carl P. Decicco、Soo S. Ko、Percy H. Carter、John V. Duncia
    DOI:10.1016/j.bmcl.2007.11.067
    日期:2008.1
    Conformational analysis of trans-1,2-disubstituted cyclohexane CCR3 antagonist 2 revealed that the cyclohexane linker could be replaced by an acyclic syn-alpha-methyl-beta-hydroxypropyl linker. Synthesis and biological evaluation of mono- and disubstituted propyl linkers support this conformational correlation. It was also found that the alpha-methyl group to the urea lowered protein binding and that
    反式1,2-二取代的环己烷CCR3拮抗剂2的构象分析表明,环己烷接头可被无环的顺式α-甲基-β-羟丙基接头取代。单取代和双取代丙基连接基的合成和生物学评估支持这种构象相关性。还发现与尿素的α-甲基降低了蛋白结合,而β-羟基降低了对CYP2D6的亲和力。从头算计算表明,α-甲基基团控制着分子内三个关键功能的空间取向。具有嗜酸性粒细胞趋化性IC(50)= 38 pM的α-甲基-β-羟丙基尿素31被选择进入临床治疗哮喘的研究。
  • Trading N and O. Part 2: Exploiting aziridinium intermediates for the synthesis of β-hydroxy-α-amino acids
    作者:Stephen G. Davies、Ai M. Fletcher、Aileen B. Frost、Paul M. Roberts、James E. Thomson
    DOI:10.1016/j.tet.2014.06.057
    日期:2014.9
    The β-hydroxy-α-amino acids (S,S)-allo-threonine, (S,S)-β-hydroxyleucine and a range of aryl substituted (S,S)-β-hydroxyphenylalanines were prepared from the corresponding enantiopure anti-α-hydroxy-β-amino esters via a rearrangement protocol, which proceeds via the intermediacy of the corresponding aziridinium ions. The starting anti-α-hydroxy-β-amino esters were prepared in >99:1 dr using our diastereoselective
    β型羟基-α氨基酸(小号,小号) -同种异体-苏氨酸,(小号,小号)-β-hydroxyleucine和取代的(一系列芳基的小号,小号)-β-hydroxyphenylalanines从相应的对映纯的制备抗-α-羟基-β-氨基酯通过重排方案,其通过相应的叠氮鎓离子的中间进行。使用我们的非对映选择性氨基羟基化方法,以> 99:1 dr制备起始的抗-α-羟基-β-氨基酯,从而共轭添加锂(R)-N-苄基-N-(α-甲基苄基)酰胺成α,β-不饱和酯,然后用(-)-樟脑磺酰基氧氮丙啶氧化所得的烯醇化物。随后的抗-α-羟基-β-氨基酯中的羟基的活化促进了叠氮鎓离子的形成[其随着C(2)处构型的反转而进行),以及中间叠氮鎓离子与H 2 O的区域选择性开环[其在C(3)处进行构型转化]给出了相应的抗-β-羟基-α-氨基酯,为单一非对映异构体(> 99:1 dr)。通过顺序的氢解和酯水解对这些底物进行脱保护
  • Trading N and O. Part 4: Asymmetric synthesis of syn-β-substituted-α-amino acids
    作者:Stephen G. Davies、Ai M. Fletcher、Catherine J. Greenaway、Matthew S. Kennedy、Christoph Mayer、Paul M. Roberts、James E. Thomson
    DOI:10.1016/j.tet.2018.04.071
    日期:2018.9
    C(2)-position. Subsequent activation of the α-hydroxy moiety as a leaving group followed by displacement by the β-amino substituent gave the corresponding aziridinium species. Regioselective in situ ring-opening of the aziridinium intermediates with either water or fluoride gave the corresponding syn-β-hydroxy-α-amino ester or syn-β-fluoro-α-amino ester, respectively, and N-deprotection and ester hydrolysis
    总共合成了九种对映体纯的顺式-β-取代-α-氨基酸,包括顺式-β-羟基-α-氨基酸和顺式-β-氟-α-氨基酸。合成这些顺式-β-取代-α-氨基酸的合成策略中的关键步骤涉及立体特异性重排,其通过相应的叠氮鎓离子的中间进行。必要的对映体纯正-α-羟基-β-氨基酯是通过相应的α,β-不饱和酯的不对称氨基羟基化反应,然后将所得抗在C(2)-位的-α-羟基-β-氨基酯 随后将α-羟基部分活化为离去基团,随后被β-氨基取代基取代,得到了相应的叠氮鎓类。用水或氟化物对氮丙啶鎓中间体进行区域选择性原位开环,分别得到相应的顺式-β-羟基-α-氨基酯或顺式-β-氟代-α-氨基酯,并进行N-脱保护和酯水解作为单一非对映异构体的目标顺式-β-取代-α-氨基酸,总收率良好。
  • Asymmetric synthesis of anti-(2S,3S)- and syn-(2R,3S)-diaminobutanoic acidThis is one of a number of contributions from the current members of the Dyson Perrins Laboratory to mark the end of almost 90 years of organic chemistry research in that building, as all its current academic staff move across South Parks Road to a new purpose-built laboratory.
    作者:Mark E. Bunnage、Anthony J. Burke、Stephen G. Davies、Nicholas L. Millican、Rebecca L. Nicholson、Paul M. Roberts、Andrew D. Smith
    DOI:10.1039/b306936m
    日期:——
    azide. Deprotection of tert-butyl (2S,3S,alphaS)-2-azido-3-aminobutanoate via Staudinger reduction, hydrogenolysis and ester hydrolysis furnishes anti-(2S,3S)-diaminobutanoic acid in 98%, de and 98% ee. The asymmetric synthesis of the diastereomeric syn-(2R,3S)-diaminobutanoic acid (98% de and 98% ee) was accomplished via functional group manipulation of tert-butyl anti-(2S,3S,alphaS)-2-hydroxy-3-N-be
    将同手性N-苄基-N-α-甲基苄基氨基锂加到(E)-肉桂酸叔丁酯或(E)-巴豆酸叔丁酯中,并用叠氮化三苯胺原位胺化,仅形成相应的2-重氮大于95%de的-3-氨基酯 叔丁基(3S,alphaR)-3-N-苄基-N-α-甲基苄基氨基-3-苯基丙酸酯或叔丁基(3S,alphaS)-3-N-苄基-的(E)-烯醇锂的胺化N-α-甲基苄氨基氨基丁酸酯与三叠氮化物以良好的收率和85%的de和> 95%的de生成(2R,3R,alphaR)-和(2S,3S,alphaS)-抗-2-叠氮基-3-氨基酯分别。或者,可以将叔丁基抗-(2S,3S,αS)-2-羟基-3-N-苄基-N-α-甲基苄基氨基丁酸酯选择性地转化为叔丁基抗-(2S,3S,αS)-2-叠氮基-3-N-苄基-N-α-甲基苄基氨基丁酸通过叠氮鎓离子的形成和与叠氮化物的区域选择性打开。(2S,3S,alphaS)-2-叠氮基-3-氨基丁酸叔丁酯通过
  • Asymmetric Synthesis of α-Amino Carbonyls (Aldehydes, Ketones and Acids) using Lithium (R)-N-benzyl-N-α-methylbenzylamide
    作者:Stephen G. Davies、Simon W. Epstein、Osamu Ichihara、Andrew D. Smith
    DOI:10.1055/s-2001-17449
    日期:——
    The diastereoselective conjugate addition of lithium (R)-N-benzyl-N-α-methylbenzylamide to α,β-unsaturated esters and subsequent enolate hydroxylation, followed by reduction and oxidative cleavage provides a facile route to N,N-protected α-amino aldehydes and ketones. Further manipulation furnishes α-amino acids in high enantiomeric excess.
    锂 (R)-N-苯甲基-N-α-甲基苯甲酰胺的非对映选择性共轭加成到 α,β-不饱和酯上,随后进行烯醇化羟基化,然后进行还原和氧化裂解,为 N,N-保护的 α 提供了一条简便的途径±-氨基醛和酮。进一步的操作提供了高对映体过量的α-氨基酸。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐